EGFR and small cell lung carcinoma: Several acquired resistance mechanisms to initial EGFR-TKIs are known, including gatekeeper mutations such as EGFR-T790M, activation of bypass signaling, epithelial mesenchymal transition and transformation to small-cell lung cancer [3,4].